O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.46 CNY 1.11% Market Closed
Market Cap: 3.5B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Obio Technology Shanghai Corp Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Income from Continuing Operations
-ÂĄ127.8m
CAGR 3-Years
N/A
CAGR 5-Years
-31%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Income from Continuing Operations
ÂĄ8.2B
CAGR 3-Years
25%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Income from Continuing Operations
ÂĄ1.8B
CAGR 3-Years
9%
CAGR 5-Years
34%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Income from Continuing Operations
ÂĄ3B
CAGR 3-Years
2%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Income from Continuing Operations
ÂĄ1B
CAGR 3-Years
-29%
CAGR 5-Years
7%
CAGR 10-Years
24%
W
WuXi XDC Cayman Inc
HKEX:2268
Income from Continuing Operations
ÂĄ283.5m
CAGR 3-Years
121%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.5B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.56 CNY
Overvaluation 17%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Income from Continuing Operations?
Income from Continuing Operations
-127.8m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Income from Continuing Operations amounts to -127.8m CNY.

What is Obio Technology Shanghai Corp Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-31%

Back to Top